Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3763682 | 0.87 | DRD2 (0.58) | DRD2DRD4DRD3SMN1; SMN2RAB9A | |
| SCHEMBL26118017 | 0.86 | TP53 (0.54) | DRD2DRD4DRD3SMN1; SMN2RAB9A | |
| SCHEMBL8955549 | 0.86 | TP53 (0.54) | DRD2DRD4DRD3SMN1; SMN2RAB9A | |
| SCHEMBL17637581 | 0.85 | DRD2 (0.61) | DRD2DRD4DRD3SMN1; SMN2RAB9A | |
| SCHEMBL4647002 | 0.84 | NR1I2 (0.46) | SMN1; SMN2NR1I2ALDH1A1RECQLTP53 | |
| SCHEMBL92209 | 0.84 | NR1I2 (0.46) | SMN1; SMN2NR1I2ALDH1A1RECQLTP53 | |
| SCHEMBL8258110 | 0.84 | MRGPRX4 (0.49) | SMN1; SMN2RAB9AKMT2ANR1I2ALDH1A1 | |
| SCHEMBL5265498 | 0.83 | HPGD (0.60) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL14536644 | 0.83 | RAB9A (0.51) | DRD2DRD4DRD3SMN1; SMN2RAB9A | |
| SCHEMBL10359383 | 0.82 | TP53 (0.66) | DRD2SMN1; SMN2RAB9ANPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2626398-B1 | THERMOCHROMIC COLOR-MEMORY COMPOSITION AND THERMOCHROMIC COLOR-MEMORY MICROCAPSULE PIGMENT ENCAPSULATING THE SAME | PILOT INK CO LTD (JP) | 2018-01-24 | — | — | EP | disclosed |
| US-8962522-B2 | Thermochromic color-memory composition and thermochromic color-memory microcapsule pigment encapsulating the same | THE PILOT INK CO., LTD. (JP) | 2015-02-24 | — | — | US | disclosed |
| US-20130210622-A1 | THERMOCHROMIC COLOR-MEMORY COMPOSITION AND THERMOCHROMIC COLOR-MEMORY MICROCAPSULE PIGMENT ENCAPSULATING THE SAME | THE PILOT INK CO., LTD. (JP) | 2013-08-15 | — | — | US | disclosed |
| EP-2626398-A1 | THERMOCHROMIC COLOR-MEMORY COMPOSITION AND THERMOCHROMIC COLOR-MEMORY MICROCAPSULE PIGMENT ENCAPSULATING THE SAME | The Pilot Ink Co., Ltd (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-8188082-B2 | 5,6,7,8-tetrahydro-imidazo[1,5-α]pyrazine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-29 | — | — | US | disclosed |
| EP-2423204-A1 | THIAZOLIDINONE DERIVATIVE | SBI Biotech Co., Ltd. (JP) | 2012-02-29 | — | — | EP | disclosed |
| EP-2125823-B1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-15 | — | — | EP | disclosed |
| US-20100093740-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-04-15 | — | — | US | disclosed |
| EP-2125823-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008078291-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-07-03 | — | — | WO | disclosed |
| EP-0391942-A1 | PROCESS FOR THE PREPARATION OF ARYLOXYACETIC ACID | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1990-10-17 | — | — | EP | disclosed |
| US-4937268-A | TREATMENT OF ASTHMA, CHRONIC BRONCHITIS | GLAXO GROUP LIMITED (GB) | 1990-06-26 | — | — | US | disclosed |
| US-4935540-A | OXIDIZING ARYLOXYETHANOL IN PRESENCE OF PALLADIUM AND THALLIU M ON CARBON CATALYST, ACIDIFYING | EASTMAN CHEMICAL COMPANY | 1990-06-19 | — | — | US | disclosed |
| WO-1989003378-A1 | PROCESS FOR THE PREPARATION OF ARYLOXYACETIC ACID | EASTMAN KODAK COMPANY (US) | 1989-04-20 | — | — | WO | disclosed |
| US-4804777-A | OXIDATION OF ARYLOXYETHANOL USING PALLADIUM, SILVER, CARBON CATALYST | EASTMAN KODAK COMPANY (US) | 1989-02-14 | — | — | US | disclosed |
| EP-0286242-A2 | Ethanolamine derivates, processes for their preparation and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 1988-10-12 | — | — | EP | disclosed |
| EP-0011793-B1 | PROCESS FOR PREPARING ARYLOXYACETIC ACIDS | BAYER AG (DE) | 1981-09-02 | — | — | EP | disclosed |
| US-4238625-A | ACTIVATORS OF LEAD AND/OR BISMUTH AND/OR THEIR COMPOUNDS FOR OXIDATION WITH PLATINUM OR PALLADIUM CATALYST | BAYER AKTIENGESELLSCHAFT (DE) | 1980-12-09 | — | — | US | disclosed |
| EP-0011793-A1 | Process for preparing aryloxyacetic acids | BAYER AG (DE) | 1980-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093740-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | HCRTR1, HCRTR2, NPY5R | DRD2 214/4885DRD4 183/4885DRD3 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.